La chaîne d'options affiche les données clés des options sur actions de Cartesian Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Cartesian Therapeutics..

Cartesian Therapeutics (NASDAQ:RNAC) Stock, Chaîne d'Options

CARTESIAN THERAPEUTICS INC

Cartesian Therapeutics

Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.

Macro Economic Events

News

Global

Economics

Reuters Cites Brazil's Suzano Exec Saying Consumer In North America Will Have To Bear The Additional Cost Stemming From Tariffs

<ul>
<li>The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR &#xAE;, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors</li>
<li>Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030</li>
<li>Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus on predicting the efficacy, safety and biomarker signatures associated with those potential treatments</li>
<li>Platform successfully guided FDA-cleared Phase 1B/2 trial design for LP-184 + olaparib in triple-negative breast cancer</li>
</ul>
Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR&#xAE; platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.lanternpharma.com%2Fnews-1%2Fnews%2Fnews-details%2F2025%2FLantern-Advances-Drug-Candidate-LP-184-with-IND-Clearance-for-Phase-1b2-Clinical-Trial-in-Triple-Negative-Breast-Cancer-TNBC-2025-3ZfXads1GN%2Fdefault.aspx&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=achieved+FDA+clearance+for+a+Phase+1B%2F2+clinical+trial+in+triple-negative+breast+cancer+%28TNBC%29&amp;index=1&amp;md5=018505482c93aeed3a9a3d6255d12b3c">achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC)</a>, focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy.

LTRN

Lantern Pharma Secures FDA Approval For Phase 1B/2 Clinical Trial For LP-184 + Olaparib In Triple-Negative Breast Cancer

<ul>
<li>The AI module, trained on 221 clinical trials, will be incorporated as part of Lantern's AI platform, RADR &#xAE;, and will initially focus on tailored combinations of DNA damaging agents and DNA repair inhibitors</li>
<li>Addresses $50+ billion combination cancer therapy market projected to grow 8.5% annually through 2030</li>
<li>Over 60% of cancer patients received DNA damaging agents or DNA repair inhibitors as part of their clinical treatment and unique AI-powered module will focus on predicting the efficacy, safety and biomarker signatures associated with those potential treatments</li>
<li>Platform successfully guided FDA-cleared Phase 1B/2 trial design for LP-184 + olaparib in triple-negative breast cancer</li>
</ul>
Lantern Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LTRN#NASDAQ">LTRN</a>), a pioneering artificial intelligence (AI) company transforming oncology drug discovery and development, today announced the launch of an innovative AI-powered module within its proprietary RADR&#xAE; platform, designed to predict the activity and efficacy of combination regimens involving DNA-damaging agents (DDAs) and DNA damage response inhibitors (DDRis) in clinical cancer treatment. With the global market for combination cancer therapies projected to exceed $50 billion by 2030, growing at a CAGR of 8.5%, this module represents a significant advancement in precision oncology, enabling faster, more cost-effective development of tailored therapeutic regimens. Leveraging this AI-driven framework, Lantern Pharma has successfully architected and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.lanternpharma.com%2Fnews-1%2Fnews%2Fnews-details%2F2025%2FLantern-Advances-Drug-Candidate-LP-184-with-IND-Clearance-for-Phase-1b2-Clinical-Trial-in-Triple-Negative-Breast-Cancer-TNBC-2025-3ZfXads1GN%2Fdefault.aspx&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=achieved+FDA+clearance+for+a+Phase+1B%2F2+clinical+trial+in+triple-negative+breast+cancer+%28TNBC%29&amp;index=1&amp;md5=018505482c93aeed3a9a3d6255d12b3c">achieved FDA clearance for a Phase 1B/2 clinical trial in triple-negative breast cancer (TNBC)</a>, focusing on a novel DDA-DDRi combination regimen with promising preclinical efficacy.
In a peer-reviewed study published in Frontiers in Oncology, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.3389%2Ffonc.2025.1577468&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=Clinical+outcomes+of+DNA-damaging+agents+and+DNA+damage+response+inhibitors+combinations+in+cancer%3A+a+data-driven+review&amp;index=2&amp;md5=decb84403c612e661b24bdd68f046d29">Clinical outcomes of DNA-damaging agents and DNA damage response inhibitors combinations in cancer: a data-driven review</a>, Lantern Pharma researchers systematically analyzed 221 DDA-DDRi combination-arm clinical trials, involving 22 DDAs and 46 DDRis, to develop this module. The study categorized DDAs into eight subclasses (e.g., alkylating agents, interstrand cross-linkers) and DDRis into 14 subclasses (e.g., PARP, ATR, WEE1 inhibitors). From these, 89 trials with interpretable outcomes were scored for clinical effectiveness, safety, and biomarker-driven responses, providing a robust dataset to train the AI module.1
Transforming Cancer Combination Therapy Development
The new AI module represents a paradigm shift in precision oncology, leveraging machine learning to predict which drug combinations will be most effective for specific patient populations while minimizing toxicity risks. This data-driven approach has already demonstrated its value by successfully guiding the design of <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.lanternpharma.com%2Fnews-1%2Fnews%2Fnews-details%2F2025%2FLantern-Advances-Drug-Candidate-LP-184-with-IND-Clearance-for-Phase-1b2-Clinical-Trial-in-Triple-Negative-Breast-Cancer-TNBC-2025-3ZfXads1GN%2Fdefault.aspx&amp;esheet=54290788&amp;newsitemid=20250715020079&amp;lan=en-US&amp;anchor=Lantern%27s+FDA-cleared+Phase+1B%2F2+clinical+trial+combining+LP-184+with+olaparib+in+triple-negative+breast+cancer&amp;index=3&amp;md5=944624f8b7c28bae6c8c8c6a7b5026be">Lantern's FDA-cleared Phase 1B/2 clinical trial combining LP-184 with olaparib in triple-negative breast cancer</a> (TNBC).

Biotech

General

Lantern Pharma Launches AI Module Trained On 221 Clinical Trials To Predict Efficacy Of DNA-Damaging Agent Combinations; Platform Already Guided FDA-Cleared Phase 1B/2 Trial In Triple-Negative Breast Cancer

Small Cap Consumer Research analyst Eric Beder reiterates Lands' End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) with a Buy and maintains $20 price target.

Price Target

Reiteration

Analyst Ratings

Small Cap Consumer Research Reiterates Buy on Lands' End, Maintains $20 Price Target

Trading Ideas

KAPA

Kairos Pharma Shares Resume Trade

RAPT

RAPT Therapeutics Shares Halted On Circuit Breaker To The Upside, Stock Now Up 29.1%

CYCC

Cyclacel Pharmaceuticals Shares Resume Then Halt Again On Circuit Breaker, Now Up 82.5%

RBC Capital analyst Elvira Scotto reiterates Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) with a Outperform and maintains $63 price target.

RBC Capital Reiterates Outperform on Williams Companies, Maintains $63 Price Target

Oppenheimer analyst Michael Wiederhorn maintains Centene (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) with a Outperform and lowers the price target from $85 to $51.

Oppenheimer Maintains Outperform on Centene, Lowers Price Target to $51

Reuters Cites Brazil's Suzano Exec Saying Brazil Represents 83% Of The Total Hardwood Pulp That U.S. Imports In A Given Year, That's A Relevant Number; Suzano Itself Will Find Ways Of Selling Those Those Products To Other Markets; But The Best Outcome Obviously Is Keeping The Relationships We Have Established For Several Years In North America; It's Very Hard To Predict From Our Side What Will Come, The The Lack Of Visibility Of The Next Steps Is A Factor

RBC Capital analyst Elvira Scotto reiterates Targa Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRGP#NYSE">TRGP</a>) with a Outperform and maintains $205 price target.

TRGP

RBC Capital Reiterates Outperform on Targa Resources, Maintains $205 Price Target

Oppenheimer analyst Tyler Batory maintains PulteGroup (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PHM#NYSE">PHM</a>) with a Outperform and raises the price target from $125 to $132.

Oppenheimer Maintains Outperform on PulteGroup, Raises Price Target to $132

Kairos Pharma Shares Halted On Circuit Breaker To The Downside, Stock Now Up 124.8%

Mizuho analyst John Roberts maintains Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) with a Outperform and raises the price target from $52 to $59.

Mizuho Maintains Outperform on Corning, Raises Price Target to $59

RBC Capital analyst Scott Hanold reiterates Range Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RRC#NYSE">RRC</a>) with a Sector Perform and maintains $45 price target.

RBC Capital Reiterates Sector Perform on Range Resources, Maintains $45 Price Target

Mizuho analyst John Roberts maintains Element Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESI#NYSE">ESI</a>) with a Outperform and raises the price target from $24 to $27.

Mizuho Maintains Outperform on Element Solutions, Raises Price Target to $27

Cyclacel Pharmaceuticals Shares Halted On Circuit Breaker To The Upside, Stock Now Up 55.3%

Mizuho analyst John Roberts maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Outperform and raises the price target from $90 to $98.

ENTG

Mizuho Maintains Outperform on Entegris, Raises Price Target to $98

Play is rolling out now and will be available to nearly 100 million vehicles by the end of 2025
The new, lower-cost plan brings subscribers over 130 music, sports, news and talk channels in-car with limited ad interruptions, plus access to the SiriusXM app
NEW YORK, July 15, 2025 /PRNewswire/ -- SiriusXM, the leading audio entertainment company in North America, today announced the launch of SiriusXM Play, the company's first low-cost, ad-supported subscription package. Welcoming new listeners to experience the company's flagship audio service at a low monthly price of less than $7, SiriusXM Play offers access to over 130 channels with limited ads in-car and even more to discover streaming in the app, delivering a compelling subset of its signature premium, curated music, talk, and sports programming at an exceptional value. For marketers, Play expands on SiriusXM's existing talk programming ad inventory to now include the previously untapped opportunity to reach consumers within its unparalleled music channels, giving advertisers a one-of-a-kind platform to meaningfully connect in the car and out with listeners across North America.

SIRI

SiriusXM Introduces SiriusXM Play, A New Low-Cost, Ad-Supported Subscription Plan; Play Available To 100M Vehicles By End Of 2025; SiriusXM Play Priced Under $7 Monthly

RBC Capital analyst Daniel Perlin reiterates Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) with a Outperform and maintains $650 price target.

RBC Capital Reiterates Outperform on Mastercard, Maintains $650 Price Target

Press Releases

Cartesian Therapeutics Announces New Employment Inducement Grant

Earnings

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cartesian Therapeutics Announces New Employment Inducement Grants

Cartesian Therapeutics' Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

Comments

Cartesian Therapeutics

Cartesian Therapeutics (RNAC) Options

Cartesian Therapeutics (NASDAQ:RNAC) Stock, Chaîne d'Options

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL